Pfizer and Dynamiker Biotechnology signed a strategic cooperation agreement on December 1, 2025.

Roche announced Tuesday that its PCR-based test for vaginitis has received CE marking. The test is now available in countries accepting the designation.

Diagnostics firm IdentifySensors Biologics has recently demonstrated proof of concept for the use of its electrochemical sensor-based diagnostic platform Check4 for cancer testing and is now moving closer to commercialization of the platform and related tests.

New research suggests that individuals who consistently carry Staphylococcus aureusin their noses have other nasal microbial community features that are distinct from those found in individuals without persistent S. aureus colonization.

In honour of World AIDS Day 2025, AIDS Healthcare Foundation (AHF) UK will host two community events to emphasize that the work to end HIV/AIDS is not over.

Sysmex and Qiagen's Japanese subsidiary said Tuesday that they have expanded their longstanding partnership to include the distribution of clinical diagnostic products for infectious diseases and cancer in Japan.

Altesa BioSciences, a clinical stage pharmaceutical company dedicated to preventing and treating rhinovirus infections, one of the leading causes of Chronic Obstructive Pulmonary Disease (COPD) and asthma exacerbations, today announced a partnership with bioMérieux, a world leader in the field of in vitro diagnostics, to utilize the BIOFIRE® SPOTFIRE® respiratory solution as its core point-of-care diagnostics platform at U.S. sites for Altesa’s upcoming Phase 2B clinical trial.

Australian molecular diagnostics developer Genetic Signatures has signed a strategic partnership with lab automation solutions provider Tecan and in vitro diagnostic software developer Repado. Announced on Tuesday, the partnership aims to create a scalable suite of fully integrated syndromic infectious disease testing systems. Financial terms were not disclosed.

Cardiovascular disease remains the leading cause of death worldwide. More than half a billion people around the world continue to be affected by cardiovascular diseases, which accounted for 20.5 million deaths in 2021 – close to a third of all deaths globally and an overall increase on the estimated 121 million CVD deaths.

To the cheers of blood centers, the US Food and Drug Administration said this week that it plans to eliminate a requirement to screen donated blood with hepatitis B virus surface antigen testing when two other testing methods are also used.